Anhui Zhifei Longcom Biopharmaceutical Co.,Ltd (hereinafter referred to as "Zhifei Longcom ") is a high-tech enterprise which integrates the R&D, production and sales of biological products, it is a wholly owned subsidiary of Chongqing Zhifei Biological products Co., Ltd (stock code :300122). The company mainly engages in the R&D and production of biological products (immune preparations, vaccines, genetic recombination products), it has a registered capital of 765 million yuan, plant area of 216,282 m2, and it has expropriated 415.7 mu of land for the construction of bio-pharmaceutical industrial Park in Hefei Hi-tech Zone. After completion, the biopharmaceutical industrial park will be integrated with R&D, production, logistics, sales and incubation, realizing a multi-variety and large-scale production pattern.At that time, the company will become a first-class vaccine enterprise in China, effectively promote the development of hefei biomedical industry, and contribute to the realization of the goal of "healthy China".
In recent years, Zhifei Longcom has received various honors and titles, such as “Certificate of High & New Technological Enterprise”, “National Key New Product Certificate”, “Innovative Pilot Enterprise of Anhui Province”, “New-type Human Vaccine Engineering Technology Research Center of Anhui Province”, “Hefei Municipal Enterprise Technical Center”, “Informatization and Industrialization Integration Model Enterprise of Hefei City”. The company has also undertaken five national major special programs for infectious disease prevention and control, and three national major special program for new drugs innovation.
The company is dedicated to the R&D and production of novel vaccines for human use. Which includes two major directions, The first is products for tuberculosis: currently on sale products are Vaccae® (Mycobacterium Vaccae for Injection), and EC-Test® (recombinant Mycobacterium tuberculosis fusion protein). Mycobacterium Vaccae for Injection is a new bi-directional immunomodulator, Mainly used for tuberculosis immunotherapy. As an immunization agent recommended by the World Health Organization (WHO) in its Tuberculosis Research and Development Strategy for tuberculosis control, it has a national invention patent, and is an exclusive listed products in domestic and foreign markets. Recombinant Mycobacterium tuberculosis fusion protein are designed for the diagnosis of mycobacterium tuberculosis infection, the skin test results were not affected by BCG vaccination, it can also be used as a clinical auxiliary diagnosis for tuberculosis. Recombinant Mycobacterium tuberculosis fusion protein has a national invention patent, it has obtained the national class I new drug certificate on April 23, 2020. And one upcoming product is mycobacterium Vaccae vaccine (for people with TB infection). The second is virus vaccines: New products under development include influenza vaccine, rabies vaccine, Norovirus vaccine, and Covid-19 vaccine, etc.
The company's product sales rely on its parent Company, Chongqing Zhifei Biological Products Co.,Ltd.Chongqing Zhifei has a comprehensive and extensive marketing network system, which can ensure the continuity and rapid penetration of new products terminal, and to provide customers with timely high quality products and detailed comprehensive services.The company firmly establishes the concept of the service for the customer, and for the public health, and carry out the service to the whole process of pre-sales, on-sales, after-sales.
Zhifei Longcom adheres to the company tenet of “Prioritize social benefits over corporate profits” and the development idea of “Focusing on R&D, promoting production, guaranteeing quality and accelerating growth”, aiming to build a world-class biopharmaceutical R&D and production platform, create national brands, provide safe, effective and quality controllable biological products for the society. Taking “Realize Zhifei Dream, Bio Dream, Health Dream and Chinese Dream” as the objective, Zhifei Longcom is committed to serving the national health and making contributions to the national health strategy.